688192 迪哲医药-U
已收盘 06-18 15:00:01
资讯
新帖
简况
股市必读：迪哲医药（688192）6月16日董秘有最新回复
证券之星 · 06-17
股市必读：迪哲医药（688192）6月16日董秘有最新回复
每周股票复盘：迪哲医药（688192）舒沃哲III期研究登NEJM
证券之星 · 06-07
每周股票复盘：迪哲医药（688192）舒沃哲III期研究登NEJM
迪哲医药泽弗罗韦一线治疗EGFR Exon20ins NSCLC疗效显著优于化疗
美股速递 · 05-29
迪哲医药泽弗罗韦一线治疗EGFR Exon20ins NSCLC疗效显著优于化疗
迪哲医药公布III期悟空28研究结果：泽弗洛维®（舒沃替尼）一线治疗EGFR Exon 20插入突变非小细胞肺癌疗效优于铂类双药化疗
美股速递 · 05-29
迪哲医药公布III期悟空28研究结果：泽弗洛维®（舒沃替尼）一线治疗EGFR Exon 20插入突变非小细胞肺癌疗效优于铂类双药化疗
迪哲医药泽弗洛维®（舒沃替尼）一线治疗EGFR外显子20插入突变非小细胞肺癌新药申请获中国国家药监局受理并纳入优先审评
美股速递 · 05-27
迪哲医药泽弗洛维®（舒沃替尼）一线治疗EGFR外显子20插入突变非小细胞肺癌新药申请获中国国家药监局受理并纳入优先审评
迪哲医药：舒沃哲新药上市申请获国家药监局受理并纳入优先审评
证券之星 · 05-27
迪哲医药：舒沃哲新药上市申请获国家药监局受理并纳入优先审评
每周股票复盘：迪哲医药（688192）舒沃哲和高瑞哲2025年销售增123%
证券之星 · 05-17
每周股票复盘：迪哲医药（688192）舒沃哲和高瑞哲2025年销售增123%
迪哲医药：5月14日召开业绩说明会
证券之星 · 05-14
迪哲医药：5月14日召开业绩说明会
迪哲医药（688192）披露血液瘤产品高瑞哲和比瑞替尼研究成果入选2026年EHA年会，5月14日股价下跌2.6%
证券之星 · 05-14
迪哲医药（688192）披露血液瘤产品高瑞哲和比瑞替尼研究成果入选2026年EHA年会，5月14日股价下跌2.6%
迪哲医药(688192.SH)：两大血液瘤核心产品研究成果入选2026年欧洲血液学协会(EHA)年会
智通财经 · 05-13
迪哲医药(688192.SH)：两大血液瘤核心产品研究成果入选2026年欧洲血液学协会(EHA)年会
每周股票复盘：迪哲医药（688192）2025年营收增122.60%
证券之星 · 05-10
每周股票复盘：迪哲医药（688192）2025年营收增122.60%
东吴证券：给予迪哲医药买入评级
证券之星 · 05-08
东吴证券：给予迪哲医药买入评级
迪哲医药（688192）披露将召开2025年度暨2026年一季度集体业绩说明会，5月6日股价上涨0.88%
证券之星 · 05-06
迪哲医药（688192）披露将召开2025年度暨2026年一季度集体业绩说明会，5月6日股价上涨0.88%
每周股票复盘：迪哲医药（688192）股东户数增8.82%，一季报营收增58.18%
证券之星 · 05-02
每周股票复盘：迪哲医药（688192）股东户数增8.82%，一季报营收增58.18%
迪哲医药(688192)3月31日股东户数1.09万户，较上期增加8.82%
证券之星 · 04-29
迪哲医药(688192)3月31日股东户数1.09万户，较上期增加8.82%
股市必读：4月24日迪哲医药现1笔折价16.03%的大宗交易 合计成交2222.66万元
证券之星 · 04-27
股市必读：4月24日迪哲医药现1笔折价16.03%的大宗交易 合计成交2222.66万元
每周股票复盘：迪哲医药（688192）多款肺癌药研究入选ASCO大会
证券之星 · 04-26
每周股票复盘：迪哲医药（688192）多款肺癌药研究入选ASCO大会
迪哲医药(688192.SH)：多项肺癌领域研究成果获选2026年美国临床肿瘤学会(ASCO)大会报告
智通财经 · 04-22
迪哲医药(688192.SH)：多项肺癌领域研究成果获选2026年美国临床肿瘤学会(ASCO)大会报告
迪哲医药（688192）披露2025年年度股东会会议资料，4月15日股价上涨3.95%
证券之星 · 04-15
迪哲医药（688192）披露2025年年度股东会会议资料，4月15日股价上涨3.95%
每周股票复盘：迪哲医药（688192）2025年主营收入8.01亿元
证券之星 · 04-05
每周股票复盘：迪哲医药（688192）2025年主营收入8.01亿元
加载更多
公司概况
公司名称：
迪哲(江苏)医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-12-10
主营业务：
迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。
发行价格：
52.58
{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药-U","latestPrice":37.96,"timestamp":1781766001000,"preClose":36.6,"halted":0,"volume":7068258,"delay":0,"changeRate":0.0372,"floatShares":461000000,"shares":465000000,"eps":-1.4341,"marketStatus":"已收盘","change":1.36,"latestTime":"06-18 15:00:01","open":36.58,"high":38.96,"low":35.95,"amount":266000000,"amplitude":0.0822,"askPrice":37.96,"askSize":134,"bidPrice":37.95,"bidSize":15,"shortable":0,"etf":0,"ttmEps":-1.4341,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":5,"adr":0,"adjPreClose":36.6,"symbolType":"stock_kcb","openAndCloseTimeList":[[1781746200000,1781753400000],[1781758800000,1781766000000]],"highLimit":40.26,"lowLimit":32.94,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":465165842,"isCdr":false,"pbRate":14.3,"roa":"--","roe":"--","epsLYR":-1.71,"committee":0.440162,"marketValue":17658000000,"turnoverRate":0.0153,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-06-22。","afterMarket":{"amount":0,"volume":0,"close":37.96,"buyVolume":0,"sellVolume":0,"time":1781768037746,"indexStatus":"已收盘 06-18 15:30:00","preClose":36.6},"floatMarketCap":17508000000},"requestUrl":"/m/hq/s/688192","defaultTab":"news","newsList":[{"id":"2644376432","title":"股市必读：迪哲医药（688192）6月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644376432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644376432?lang=zh_cn&edition=full","pubTime":"2026-06-17 01:57","pubTimestamp":1781632634,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，迪哲医药报收于36.95元，下跌2.58%，换手率1.06%，成交量4.88万手，成交额1.81亿元。董秘最新回复投资者： 尊敬的公司领导：作为一名公司投资者，很关心公司发展。公司正在积极准备向美国食品药品监督管理局递交新增适应症上市申请，后续进展我们将及时进行信息披露告知广大投资者。当日关注点交易信息汇总：6月16日主力资金净流出1532.02万元，游资资金净流入583.04万元，散户资金净流入948.98万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700000777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127364","title":"每周股票复盘：迪哲医药（688192）舒沃哲III期研究登NEJM","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127364","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641127364?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:10","pubTimestamp":1780769425,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，迪哲医药报收于39.49元，较上周的55.53元下跌28.89%。本周，迪哲医药6月1日盘中最高价报57.22元。舒沃哲国际多中心III期研究“悟空28”以口头报告形式发布，并发表于《新英格兰医学杂志》，显示其在EGFR exon20ins NSCLC一线治疗中显著改善无进展生存期和客观缓解率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184495041","title":"迪哲医药泽弗罗韦一线治疗EGFR Exon20ins NSCLC疗效显著优于化疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1184495041","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184495041?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:54","pubTimestamp":1780059272,"startTime":"0","endTime":"0","summary":"迪哲医药宣布，其核心候选药物泽弗罗韦在一线治疗EGFR Exon20ins非小细胞肺癌的临床试验中，显示出相较于标准化疗方案更优的疗效。这一积极数据进一步验证了该药物在解决这一特定难治性肺癌亚型方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156054701","title":"迪哲医药公布III期悟空28研究结果：泽弗洛维®（舒沃替尼）一线治疗EGFR Exon 20插入突变非小细胞肺癌疗效优于铂类双药化疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1156054701","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156054701?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:53","pubTimestamp":1780059200,"startTime":"0","endTime":"0","summary":"迪哲医药宣布，其III期临床研究“悟空28”取得积极结果。数据显示，该公司核心产品泽弗洛维®（舒沃替尼）作为一线疗法，在治疗携带EGFR Exon 20插入突变的非小细胞肺癌患者时，其疗效显著优于标准的铂类双药化疗方案。这一关键性研究成果为这类难治性肺癌患者提供了新的、更具潜力的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111369957","title":"迪哲医药泽弗洛维®（舒沃替尼）一线治疗EGFR外显子20插入突变非小细胞肺癌新药申请获中国国家药监局受理并纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1111369957","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111369957?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:42","pubTimestamp":1779878544,"startTime":"0","endTime":"0","summary":"迪哲医药（江苏）股份有限公司宣布，其自主研发的创新药泽弗洛维用于一线治疗携带EGFR外显子20插入突变的非小细胞肺癌的新药上市申请，已获得中国国家药品监督管理局正式受理，并被纳入优先审评程序。该研究结果表明，泽弗洛维在一线治疗EGFR Exon20ins突变NSCLC患者中，展现了优异的抗肿瘤活性和可控的安全性特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638825501","title":"迪哲医药：舒沃哲新药上市申请获国家药监局受理并纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2638825501","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638825501?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:31","pubTimestamp":1779877886,"startTime":"0","endTime":"0","summary":"迪哲医药(688192.SH)公告称，公司自主研发的舒沃哲(舒沃替尼片)新增适应症新药上市申请获国家药监局药品审评中心正式受理，并纳入优先审评程序，用于EGFRexon20ins非小细胞肺癌一线治疗。该申请基于III期研究“悟空28”的积极结果，舒沃哲在无进展生存期上展现出显著改善。目前，全球尚无口服靶向药获批用于该领域一线治疗。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700038789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636206438","title":"每周股票复盘：迪哲医药（688192）舒沃哲和高瑞哲2025年销售增123%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636206438","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636206438?lang=zh_cn&edition=full","pubTime":"2026-05-17 03:03","pubTimestamp":1778958191,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，迪哲医药报收于53.32元，较上周的54.32元下跌1.84%。本周，迪哲医药5月14日盘中最高价报58.58元。本周关注点来自业绩披露要点：舒沃哲和高瑞哲2025年合计实现8.01亿元销售收入，同比增长123%。来自机构调研要点：公司2025年净亏损同比减少18%。答：2025年是公司两款商业化产品舒沃哲和高瑞哲纳入国家医保药品目录的第一个完整年度，合计实现8.01亿元销售收入，同比增长123%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700000885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635102067","title":"迪哲医药：5月14日召开业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2635102067","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635102067?lang=zh_cn&edition=full","pubTime":"2026-05-14 21:02","pubTimestamp":1778763746,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年5月14日迪哲医药发布公告称公司于2026年5月14日召开业绩说明会。纳入国家医保药品目录，公司2025年实现销售收入8.01亿元，同比增长123%。迪哲医药主营业务：专注于恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。迪哲医药2026年一季报显示，一季度公司主营收入2.53亿元，同比上升58.18%；归母净利润-9555.74万元，同比上升50.36%；扣非净利润-1.09亿元，同比上升50.41%；负债率59.01%，财务费用712.85万元，毛利率95.92%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400041296.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635716314","title":"迪哲医药（688192）披露血液瘤产品高瑞哲和比瑞替尼研究成果入选2026年EHA年会，5月14日股价下跌2.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635716314","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635716314?lang=zh_cn&edition=full","pubTime":"2026-05-14 18:35","pubTimestamp":1778754918,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，迪哲医药报收于55.11元，较前一交易日下跌2.6%，最新总市值为256.35亿元。该股当日开盘56.57元，最高58.58元，最低54.86元，成交额达2.1亿元，换手率为0.81%。迪哲医药于2026年5月14日发布《自愿披露关于血液瘤产品高瑞哲和比瑞替尼研究成果入选2026年欧洲血液学协会年会的公告》。相关研究将在EHA年会以壁报形式展示。公司提示药品研发存在不确定性，敬请投资者注意风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400035262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635920958","title":"迪哲医药(688192.SH)：两大血液瘤核心产品研究成果入选2026年欧洲血液学协会(EHA)年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2635920958","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635920958?lang=zh_cn&edition=full","pubTime":"2026-05-13 15:50","pubTimestamp":1778658622,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)公告，公司血液肿瘤管线中的两大核心产品——高瑞哲®(通用名：戈利昔替尼胶囊)和比瑞替尼(birelentinib)，共有9项最新研究成果入选2026年欧洲血液学协会(EHA)年会。大会将于6月11日至14日在瑞典斯德哥尔摩举行。此次入选研究覆盖外周T细胞淋巴瘤(PTCL)及B细胞淋巴瘤治疗领域的多线治疗策略及多亚型探索，进一步体现了公司在血液肿瘤领域全球创新布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634412520","title":"每周股票复盘：迪哲医药（688192）2025年营收增122.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634412520","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634412520?lang=zh_cn&edition=full","pubTime":"2026-05-10 03:23","pubTimestamp":1778354589,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，迪哲医药报收于54.32元，较上周的56.7元下跌4.2%。本周关注点来自公司公告汇总：迪哲医药2025年营业收入同比增长122.60%。来自公司公告汇总：迪哲医药将于2026年5月14日召开2025年度暨2026年一季度业绩说明会。2025年营业收入同比增长122.60%，研发投入为8.56亿元。迪哲（江苏）医药股份有限公司将于2026年5月14日15:00-16:15通过上证路演中心以视频和线上文字互动方式召开2025年度暨2026年一季度集体业绩说明会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000001344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432875","title":"东吴证券：给予迪哲医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432875","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633432875?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:10","pubTimestamp":1778235049,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对迪哲医药进行研究并发布了研究报告《2025年年报及2026年一季报点评：核心产品放量亮眼，研发管线后续催化密集》，给予迪哲医药买入评级。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为83.0。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800033100.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633344701","title":"迪哲医药（688192）披露将召开2025年度暨2026年一季度集体业绩说明会，5月6日股价上涨0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633344701","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633344701?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:48","pubTimestamp":1778078899,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，迪哲医药报收于57.2元，较前一交易日上涨0.88%，最新总市值为266.07亿元。该股当日开盘56.69元，最高58.19元，最低55.7元，成交额达2.13亿元，换手率为0.81%。公告显示，公司将于2026年5月14日15:00-16:15通过上证路演中心以视频和线上文字互动方式召开2025年度暨2026年一季度集体业绩说明会。投资者可于2026年5月13日16:00前通过邮件提交问题，公司将在说明会上对普遍关注的问题进行回应。说明会结束后，投资者可通过上证路演中心查看会议内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600040152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632258706","title":"每周股票复盘：迪哲医药（688192）股东户数增8.82%，一季报营收增58.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632258706","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632258706?lang=zh_cn&edition=full","pubTime":"2026-05-02 06:41","pubTimestamp":1777675268,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，迪哲医药报收于56.7元，较上周的55.6元上涨1.98%。本周，迪哲医药4月30日盘中最高价报59.1元。迪哲医药当前最新总市值263.75亿元，在化学制药板块市值排名17/150，在两市A股市值排名829/5200。业绩披露要点财务报告迪哲医药2026年一季报显示，一季度公司主营收入2.53亿元，同比上升58.18%；归母净利润-9555.74万元，同比上升50.36%；扣非净利润-1.09亿元，同比上升50.41%；负债率59.01%，财务费用712.85万元，毛利率95.92%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631596344","title":"迪哲医药(688192)3月31日股东户数1.09万户，较上期增加8.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631596344","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631596344?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:42","pubTimestamp":1777455773,"startTime":"0","endTime":"0","summary":"证券之星消息，近日迪哲医药披露，截至2026年3月31日公司股东户数为1.09万户，较2月28日增加883.0户，增幅为8.82%。在化学制药行业个股中，迪哲医药股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.6万户。从股价来看，2026年2月28日至2026年3月31日，迪哲医药区间涨幅为6.46%，在此期间股东户数增加883.0户，增幅为8.82%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900055379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630833933","title":"股市必读：4月24日迪哲医药现1笔折价16.03%的大宗交易 合计成交2222.66万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630833933","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630833933?lang=zh_cn&edition=full","pubTime":"2026-04-27 04:21","pubTimestamp":1777234869,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，迪哲医药报收于55.6元，下跌2.15%，换手率0.62%，成交量2.88万手，成交额1.61亿元。交易信息汇总资金流向4月24日主力资金净流出1087.1万元，占总成交额6.73%；游资资金净流出874.81万元，占总成交额5.42%；散户资金净流入1961.91万元，占总成交额12.15%。大宗交易4月24日迪哲医药现1笔折价16.03%的大宗交易，合计成交2222.66万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700005809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630804520","title":"每周股票复盘：迪哲医药（688192）多款肺癌药研究入选ASCO大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2630804520","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630804520?lang=zh_cn&edition=full","pubTime":"2026-04-26 03:38","pubTimestamp":1777145892,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，迪哲医药报收于55.6元，较上周的59.06元下跌5.86%。本周，迪哲医药4月20日盘中最高价报60.19元。本周关注点交易信息汇总：4月23日及24日迪哲医药连续两日出现折价超16%的大宗交易。4月23日迪哲医药发生1笔折价16.3%的大宗交易，合计成交3376.76万元。公司公告汇总迪哲医药自愿披露，其自主研发产品舒沃哲、高瑞哲及DZD6008在非小细胞肺癌领域的多项研究成果获选2026年美国临床肿瘤学会大会报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629006195","title":"迪哲医药(688192.SH)：多项肺癌领域研究成果获选2026年美国临床肿瘤学会(ASCO)大会报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2629006195","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629006195?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:57","pubTimestamp":1776815821,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 迪哲医药 发布公告，公司将在2026 年5月29日至6月2日于芝加哥举行的美国临床肿瘤学会年会上，公布其自主研发产品舒沃哲、高瑞哲以及DZD6008在非小细胞肺癌领域的最新研究成果，其中2项将以口头报告形式公布。此外，公司还将在大会上公布一项高瑞哲联合抗PD-1抗体一线治疗无驱动基因突变NSCLC的最新研究进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431656.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627407694","title":"迪哲医药（688192）披露2025年年度股东会会议资料，4月15日股价上涨3.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627407694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627407694?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:05","pubTimestamp":1776243940,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，迪哲医药报收于60.2元，较前一交易日上涨3.95%，最新总市值为280.03亿元。该股当日开盘59.5元，最高60.98元，最低57.0元，成交额达3.21亿元，换手率为1.17%。迪哲医药于2026年4月15日披露《2025年年度股东会会议资料》。公司2025年度实现营业收入8.01亿元，同比增长122.60%，首次实现商业化盈利，但因累计未分配利润为负，2025年度不进行利润分配。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500030394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625619913","title":"每周股票复盘：迪哲医药（688192）2025年主营收入8.01亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2625619913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625619913?lang=zh_cn&edition=full","pubTime":"2026-04-05 03:07","pubTimestamp":1775329631,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，迪哲医药报收于57.5元，较上周的56.0元上涨2.68%。本周，迪哲医药4月2日盘中最高价报59.56元。本周关注点来自业绩披露要点：迪哲医药2025年主营收入8.01亿元，同比上升122.6%。业绩披露要点财务报告迪哲医药2025年年报显示，公司主营收入8.01亿元，同比上升122.6%；归母净利润-7.64亿元，同比上升9.68%；扣非净利润-8.42亿元，同比上升6.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781990362044,"stockEarnings":[{"period":"1week","weight":0.0229},{"period":"1month","weight":-0.2548},{"period":"3month","weight":-0.2196},{"period":"6month","weight":-0.3511},{"period":"1year","weight":-0.3766},{"period":"ytd","weight":-0.341}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.019},{"period":"3month","weight":0.0337},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2071},{"period":"ytd","weight":0.0306}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10895人(较上一季度增加8.82%)","perCapita":"42332股","listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","registeredCapital":"46516万元","survey":" 迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。","listedPrice":52.58},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药-U(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药-U(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药-U,688192,迪哲医药-U股票,迪哲医药-U股票老虎,迪哲医药-U股票老虎国际,迪哲医药-U行情,迪哲医药-U股票行情,迪哲医药-U股价,迪哲医药-U股市,迪哲医药-U股票价格,迪哲医药-U股票交易,迪哲医药-U股票购买,迪哲医药-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药-U(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药-U(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}